Gilead Sciences (GILD) Fundamental Analysis: Revenue, Earnings & Valuation

2.35 / 10

Underperform

Fundamental analysis rates GILD as Underperform, scoring 2.4/10. Cash‑MV and fixed‑asset turnover are modest positives, but PB‑ROE and Revenue‑MV lag, dragging the overall fund score to 2.35. The data signals challenging earnings quality and limited upside.

Analysis Checks(6/10)

Revenue-MV

Value-0.24

Score0/3

Weight13.45%

1M Return6.46%

Inventory turnover ratio

Value3.58

Score2/3

Weight-1.53%

1M Return-1.00%

Gross profit margin (%)

Value78.83

Score0/3

Weight-8.07%

1M Return-6.17%

Net income-Revenue

Value1.11

Score3/3

Weight32.81%

1M Return11.79%

PB-ROE

Value1.53

Score1/3

Weight16.42%

1M Return7.84%

Income tax / Total profit (%)

Value13.13

Score3/3

Weight6.92%

1M Return3.56%

Fixed assets turnover ratio

Value5.34

Score2/3

Weight0.60%

1M Return0.34%

Cost of sales ratio (%)

Value21.17

Score2/3

Weight-5.16%

1M Return-3.47%

Asset-MV

Value-0.55

Score1/3

Weight27.82%

1M Return12.69%

Cash-MV

Value0.36

Score2/3

Weight16.74%

1M Return8.03%

Is GILD undervalued or overvalued?

GILD scores 2.35/10 on fundamentals and holds a Premium valuation at present. Backed by its 40.66% ROE, 28.90% net margin, 20.17 P/E ratio, 7.59 P/B ratio, and 1700.00% earnings growth, these metrics solidify its Underperform investment rating.